Search results
Director and Professor of Applied Cancer Research
- Professor Nitzan Rosenfled is Director and Professor of Applied Cancer Research at Barts Cancer Institute, Queen Mary University of London.
People also ask
Who is Professor Nitzan Rosenfeld?
Who is Professor Rosenfeld?
Who is Richard Rosenfeld?
Who is Dr Thomas Rosenfeld?
Why should I choose Dr. Rosenfeld?
Who is Sam Rosenfeld?
Professor Nitzan Rosenfled is Director and Professor of Applied Cancer Research at Barts Cancer Institute, Queen Mary University of London.
Sep 22, 2023 · Queen Mary University of London is delighted to announce the appointment of Professor Nitzan Rosenfeld as the new Director of the Barts Cancer Institute from 1 February 2024.
Sep 22, 2023 · Professor Nitzan Rosenfeld has been appointed as Queen Mary University of London’s new Director of the Barts Cancer Institute. He starts his appointment on 1 February 2024.
Professor Nitzan Rosenfeld. Director of Barts Cancer Institute. Professor Rosenfeld graduated in physics before undertaking a PhD in Systems Biology at the Weizmann Institute of Science in Israel. He then switched fields to translational cancer research while working at Rosetta Genomics.
Apr 2, 2024 · We are pleased to welcome Professor Nitzan Rosenfeld as the new Director of the Barts Cancer Institute at Queen Mary University of London. We spoke to Professor Rosenfeld to hear more about his journey leading him to the Barts Cancer Institute.
Sep 22, 2023 · We are delighted to announce the appointment of Professor Nitzan Rosenfeld as the new Director of the Barts Cancer Institute, Queen Mary University of London, on 1 February 2024. Professor Rosenfeld graduated in physics before undertaking a PhD in Systems Biology at the Weizmann Institute of Science in Israel.
Nitzan Rosenfeld is a Senior Group Leader at Cancer Research UK Cambridge Institute. He is a pioneer and world leader in developing liquid biopsy tests for cancer using circulating tumour DNA. He has developed multiple clinical diagnostic tests for cancer, based on microRNA expression profiling and on circulating cell-free tumour DNA in plasma.
